Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN44,4144,450,82
Msft2,28
Nokia3,233,2395-1,58
IBM0,73
Daimler AG44,1344,14-0,67
PFE0,81
26.09.2020 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 25.09.2020 21:59:59
Danaher Corp (DHR, NY Consolidated)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
207,28 1,77 3,61 1 995 255
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.09.2020
Popis společnosti
Obecné informace
Název společnostiDanaher Corporation
TickerDHR
Kmenové akcie:Ordinary Shares
RICDHR
ISINUS2358511028
Prioritní akciePreferred Shares Series A
TickerDHR PR A
RICDHR_pa
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky03.07.2020
Počet zaměstnanců k 31.12.2019 60 000
Akcie v oběhu k 17.07.2020 709 408 837
Počet akcionářů k 31.12.2019 2 431
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice2200 Pennsylvania Ave NW Ste 800w
MěstoWASHINGTON
PSČ20037-1731
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 028 280 850
Fax12028280860

Business Summary: Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through three segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification. Danaher's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries.
Financial Summary: BRIEF: For the six months ended 03 July 2020, Danaher Corporation revenues increased 11% to $9.64B. Net income applicable to common stockholders excluding extraordinary items increased 50% to $1.47B. Revenues reflect Life Sciences segment increase of 29% to $4.29B, Diagnostics segment increase of 4% to $3.29B. Net income benefited from Life Sciences segment income increase of 13% to $738M, Diagnostics segment income increase of 6% to $544.4M.
Odvětvová klasifikace
TRBC2009Industrial Machinery / Equipment
TRBC2012Advanced Medical Equipment & Technology - NEC
RBSS2004Industrial Machinery & Equipment
MGINDUSTRYScientific & Technical Instr.
MGSECTORTechnology
NAICSInstruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
NAICSOther Commercial and Service Industry Machinery Manufacturing
NAICSPetroleum and Petroleum Products (except Bulk Stations and Terminals) Wholesalers
NAICSTesting Laboratories
NAICSInstrument Manufacturing for Measuring and Testing Electricity and Electrical Signals
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSAll Other Business Support Services
NAICSHand and Edge Tool Manufacturing
NAICSOffices of Other Holding Companies
SICProcess Control Instruments
SICProcess Control Instruments
SICService Industry MacHinery, Nec
SICPetroleum Products, Nec
SICTesting Laboratories
SICInstruments To Measure Electric
SICElectromedical Equipment
SICBusiness Services, Nec
SICHand And Edge Tools, Nec
SICHolding Companies, Nec



  • Poslední aktualizace: 26.09.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardSteven Rales69
President, Chief Executive Officer, DirectorRainer Blair5501.09.2020
Chief Financial Officer, Executive Vice PresidentMatthew McGrew4801.01.201901.01.2019
Executive Vice PresidentDaniel Comas5631.12.201801.01.1996
Executive Vice PresidentJoakim Weidemanis5028.11.201728.11.2017
Senior Vice President, Chief Accounting OfficerRobert Lutz62
Senior Vice President, Chief Compliance Officer, General CounselBrian Ellis53
Senior Vice President - Human ResourcesAngela Lalor5404.04.201204.04.2012
Senior Vice President - Strategic DevelopmentWilliam King52
Senior Vice President - Corporate DevelopmentDaniel Raskas5301.11.2004